Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

2015206 citationsJournal Articlegreen Open Access

Authors

Victoria Tovar · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Helena Cornellà · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Agrin Moeini · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Samuel J. Vidal · Icahn School of Medicine at Mount Sinai

Yujin Hoshida · Icahn School of Medicine at Mount Sinai

Daniela Sia · Universitat de Barcelona

Abstract

Acquired resistance to sorafenib is driven by T-ICs with enrichment of progenitor markers and activation of IGF and FGF signalling. Inhibition of these pathways would benefit a subset of patients after sorafenib progression.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver physiology and pathology PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Gut

Volume 66, Issue 3, pp. 530-540

DOI: 10.1136/gutjnl-2015-309501

Field-Weighted Citation Impact: 6.56